Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technolo... More >>

Recent NewsMore >>
11/21/14LabCorp Completes Acquisition of LIPOSCIENCE
BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 21, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014. At a special meeting held on November 20, 2014, LIPOSCIENCE’s stockholders approved the acquisition and the transaction closed promptly thereafter. After the close of the Nasdaq Global Market on November 20, 201... 
Printer Friendly Version
11/03/14LabCorp to Acquire Covance for Approximately $5.6 Billion, Creating World’s Leading Healthcare Diagnostics Company
Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share Combination creates comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics development and commercialization Transaction expected to be accretive to LabCorp earnings in 2015 Price represents 32% premium to Covance’s closing stock price on ... 
Printer Friendly Version
10/28/14Laboratory Corporation of America® Holdings Announces 2014 Third Quarter Results and Increases 2014 EPS Guidance
Strong volume growth drives sales of $1.55 billion Diluted EPS of $1.59; Adjusted EPS of $1.80 Operating Cash Flow of $176 million; Free Cash Flow of $123 million 2014 Adjusted EPS guidance raised to $6.70 - $6.80 BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 28, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended Septemb... 
Printer Friendly Version
10/20/14LabCorp Introduces HIV-1 Next Generation Sequencing Assay to Support Drug Regimen Changes in HIV Suppressed Patients
GenoSure ArchiveSM is the first genotypic drug resistance assay to interrogate HIV-1 DNA BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 20, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and Monogram Biosciences, Inc., part of the LabCorp Specialty Testing Group, today announced the launch of HIV GenoSure ArchiveSM, the first laboratory test to help optimize antiretroviral (ARV) drug regimens in virally suppressed HIV patien... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
LH (Common)
Change Stock is Down 0.18
Intraday High$102.00
Intraday Low$100.35
Data as of 11/21/14
4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release